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Androgen deprivation therapy (ADT) facilitates the response of prostate cancer (PC) to radiation.
Androgens have been shown to induce elevated basal levels of reactive oxygen species (ROS) in
PC, leading to adaptation to radiation-induced cytotoxic oxidative stress. Here, we show that
androgens increase the expression of p22
phox and gp91
phox subunits of NADPH oxidase (NOX) and
ROS production by NOX2 and NOX4 in PC. Pre-radiation treatment of 22Rv1 human PC cells with
NOX inhibitors sensitize the cells to radiation similarly to ADT, suggesting that their future usage
may spare the need for adjuvant ADT in PC patients undergoing radiation.
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Introduction
With the advent of PSA screening, most prostate cancers
(PC) are currently diagnosed at a localized stage, for
which total-gland radiation or surgical removal are the
gold standard therapies. Nevertheless, even with the use
state-of-the-art high-dose conformal radiation therapy,
treatment failure occurs in 45% of patients, particularly in
those with locally advanced disease.
1 It is well estab-
lished that the use of androgen deprivation therapy
(ADT) concurrently with radiation, improves overall
survival in patients with locally advanced disease
compared with patients who received radiation alone.
2,3,4
Potential reasons for this include, but are not restricted to,
the anti-angiogenic
5 and pro-apoptotic
6 effects of ADT, as
well as to cyto-reduction and control of micrometastatic
disease.
7 We have recently suggested another potential
mechanism for the radiosensitizing effect of ADT, namely
that ADT enhances the vulnerability of PC cells to toxic
oxidative stress induced by radiation.
8 Ionizing radiation
exposure of cells/tissues generates multiple highly
reactive oxygen species (ROS) from cellular water, which
oxidize DNA, proteins and lipids. This translates into
toxic oxidative damage in the cancer cells by DNA strand
breaks, disruption of plasma, mitochondrial, nuclear, and
endoplasmic reticulum membranes and protein cross
links, leading to increased membrane permeability and
loss of function, as well as alteration of cellular protein
functions and their degradation.
We have showed that androgens increase the basal
levels of ROS, which consequently stimulates the
activation and the expression of stress molecules and
anti-oxidative enzymes to better cope with the shift in
redox balance. Thus, upon radiation these cells become
less sensitive to toxic levels of ROS compared with
androgen-deprived cells and so are less susceptible to
treatment by radiation.
8
One of the major sources of basal ROS generation in
P Cc e l l si st h eN A D P Ho x i d a s e( N O X )s y s t e m .
9 NOX are
a family of multi-component transmembrane enzymes
that transport electrons across biological membranes to
generate super-oxide O2( ) by the reduction of oxygen.
10,11
NOX can be activated by various growth factors,
12 but
to the best of our knowledge it is unknown whether
androgens can enhance the generation of ROS by NOX in
human PC. The present study sought to determine if
androgens stimulate ROS generation in PC cells through
NOX, and whether inhibition of NOX can increase the
response of PC cells to radiation. We found that androgens
increase and ADT decreases the in-vitro and in-vivo expres-
sion of the p22
phox catalytic subunits of NOX, and the
mRNA levels of NOX2 and NOX4 in 22Rv1 human PC cells.
Inhibition of NOX by apocynin, sensitized these cells in-vitro
to radiation to a similar extent as androgen deprivation.
Materials and methods
Cell lines and xenografts
22Rv1 human PC cells (ATTC, Manassas, VA, USA) were
cultured at 371C in a typical CO2 incubator with 5% CO2
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red-free RPMI-1640 with 2mML -glutamine adjusted to
contain 1.5gl
 1 sodium bicarbonate, 4.5gl
 1 glucose,
10mM HEPES, 1.0mM sodium pyruvate (all from
Invitrogen, Burlington, ON, Canada) and 10% charcoal-
stripped fetal calf serum (CSFCS, Hyclone, UT,
USA). CWR22,
13 WISH-PC14 and WISH-PC23
14 human
prostate adenocarcinomas were grown as subcutaneous
xenografts in castrated and testosterone-supplemented
male (CB.17–SCID BEIGE) mice within the stem and
progenitor cells (SPC) colony of the Weizmann Institute
of Science, Israel in compliance with institutional guide-
lines. Professor Eshhar (Weizmann Institute) provided
frozen samples of these xenografts.
Hormonal treatments
In vitro. Cells were grown for 48–72h in an androgen-
depleted medium comprising of phenol-free medium
and 10% CSFCS. The normal value for testosterone in the
serum of adult males is 14–35nM. Thus, to create an
androgen-supplemented medium, testosterone (R1881;
Sigma, Oakville, ON, Canada) was added to a final
concentration of 10nM. To block the effects of testoster-
one, the androgen receptor (AR) blocker bicalutamide
(AstraZeneca, Macclesfield, Cheshire, UK) was added to
a final concentration of 10mM, mimicking the mean
plasma concentration (50.2 mM) in PC patients treated
with bicalutamide monotherapy (150mg daily).
15
In vivo. CWR22, WISH-PC14 and WISH-PC23 xeno-
grafts were grown in 7–10 week old male mice (CB.17–
SCID BEIGE) that underwent bilateral orchiectomy or
transplanted subcutaneously with 90-day slow-release
testosterone pellets (12.5mg per pellet; Innovative
Research of America, Sarasote, FL, USA), as previously
described.
16
Inhibition of NOX
In some experiments, two different compounds were
used to inhibit NOX: apocynin (Sigma, Oakville, ON,
Canada) and diphenyleneiodonium (DPI, Sigma). Cells
were grown for 48–72h under different hormonal
manipulations described above. In this timeframe, cells
were treated for the final 24h with either apocynin at a
concentration of 200mM or DPI at a concentration of
10mM. As control, we used the reducing agent N-
acetylcysteine (NAC, Sigma) at a concentration of
5m M, which is a general ROS quencher.
In vitro detection of ROS
Both the nitroblue tetrazolium (NBT, Sigma) and
dihydroethidium (DHE, Sigma) confocal microscopy
assays were used to detect ROS, as we previously
described,
8 under different hormonal manipulations
with and without treatment with apocynin, DPI or NAC
as described above. Briefly, cells were grown to a
confluence in 96-well plates and then incubated for
90min in PBS containing 0.1% NBT. The reduction of
NBT by ROS induces a proportional change in the
absorption of light at 620nm in the medium. Results are
expressed as mean±s.d. after controlling for the meta-
bolic activity of the cells in each hormonal condition
using the WST-1 assay (Roche, Mississauga, ON,
Canada), by the following calculation: (Value sample 
Value background)/Value of the samples’ metabolic
activity.
For the DHE confocal microscopy assay, cells were
grown to confluence and then trypsinized and equal
numbers of cells were placed on glass coverslips at
a density of 10
3cellsmm
 2. After 24h the cells were
loaded with 10mM DHE (Molecular Probes, Invitrogen,
Burlington, ON, Canada) for 30min at 371C. Cells were
washed and fluorescence was measured using 488nm
argon/crypton laser. Images were analyzed using Image
Pro software. Results are expressed as mean±s.d. after
controlling for the metabolic activity of the cells in each
hormonal condition using the WST-1 test (Roche) by the
following calculation: (Value sample-Value back-
ground)/Value of the samples’ metabolic activity.
Immunoblot assays
Cells were grown to sub-confluence under the different
hormonal conditions described above. After two washes
with ice-cold PBS, cells were lysed in 1% Triton X-100/
PBS lysis buffer supplemented with an anti-proteases
and anti-phosphatases cocktail (Sigma) for 30min at 41C.
Following centrifuging at 12000g for 15min and separa-
tion insoluble materials and supernatants were dissolved
in Laemmli sample buffer. Protein purification from
tumor tissues was carried using a protein extraction kit
(Biochain Institute, Greenland, NH, USA). Equivalent
amounts of protein (30–50mg) were resolved by sodium
dodecyl sulfate polyacrylamide electrophoresis in 8–12%
gels (80V for 20min; 100V for 1h) and transferred by
electroblotting (1.5h at 100V) to a polyvinylidene
fluoride membrane. After blocking nonspecific binding
using Tris-buffered saline (TBS) containing 0.05% Tween-
20 (TBS-T) and 5% nonfat powdered milk, the blot was
incubated with primary antibody against p22
phox (1:1000,
Cat #20781, Santa Cruz, CA, USA) and gp91
phox (1:1000,
#20782, Santa Cruz) at 41C overnight or at room
temperature for 1h. The membrane was then washed
multiple times with TBS-T and incubated with appro-
priate horseradish peroxidase-conjugated secondary
antibodies: goat anti-mouse or goat anti-rabbit (Sigma),
both at 1:1000 dilutions for 1h at room temperature.
Protein-antibody complexes were detected with an
enhanced chemiluminescence kit (Amersham, Arlington
Heights, IL, USA) according to the manufacturer’s
recommended protocol. All quantifications of western
blot analysis were carried out by reprobing the blots with
1:1000 mouse anti-b-actin antibody (Sigma) to ensure
equal protein loading, followed by scanning and
densitometry using Quantity-One software (Bio-Rad,
Hercules, CA, USA).
Reverse transcriptase-PCR
Total RNAwas isolated using the RNAspin Mini Kit (GE
healthcare, Buckinghamshire, UK). cDNA was prepared
from total RNA (2mg) by reverse-transcription using
superscript reverse transcriptase (Invitrogen). PCR
was performed with the cDNA, TaqDNA polymerase
(Promega, Madison, WI, USA) using the primers des-
cribed by Vaquero et al.
12 Relative amount of cDNA
Androgens and NADPH oxidase in prostate cancer
JP Lu et al
40
Prostate Cancer and Prostatic Diseasesrepresenting the transcript expression level of mRNA
was analyzed following 24, 28 or 36 PCR cycles. The
PCR products were separated using 3% agarose gel
electrophoresis. Representative images are displayed
from at least three repetitions each from three different
experiments.
Clonogenic radiation assay
Plated 22Rv1 cells that were hormonally pretreated for
48h underwent a single dose of 3 Gy g-radiation using a
137Cs irradiator at 1 Gy/min at room temperature. Plates
were then incubated at 371C for 14 days. Medium was
replaced every 4 to 5 days. At the end of this period,
colonies (defined as a cluster of greater than 50 cells)
were counted after fixation and staining (methylene
blue/50% methanol). Radiation survival was calculated
as the plating efficiency of treated cells divided by the
plating efficiency of untreated cells as previously
described.
17
Data analysis
Results are derived from at least three separate experi-
ments and are expressed as mean±s.d. Statistical
analysis was done using paired Student’s t-test with
Po0.05 considered significant.
Results
Androgens induce the production of ROS by NOX
In accordance with our previous report,
8 treatment
of 22Rv1 cells with physiologic levels of androgens
(10
 8 M R1881) significantly increased the levels of
ROS production compared with androgen-deprived cells
(P¼0.0001 in both the NBTand DHE assays) or cells that
were treated with the combination of 10
 8 M R1881 and
10
 5 M bicalutamide (P¼0.002 and P¼0.015 in the NBT
and DHE assays respectively) (Figure 1). To test if the
effect of androgens on ROS production is mediated
through NOX, we concurrently treated the cells with
two structurally-unrelated inhibitors of NOX (DPI and
apocynin), as well as the general antioxidant N-acetyl-
cysteine under all hormonal conditions. This led to
marked suppression of ROS production in all cases,
suggesting that NOX enzymes are indeed a source of
ROS production in these cells (Figure 1).
Androgens increase the expression of NOX2 and NOX4
Once we confirmed that androgens induced the produc-
tion of ROS by NOX, we characterized the specific
sub-types of NOX in our model. In the absence of
adequate antibodies to NOX1, 3, 4 and 5 we examined
the expression of NOX1–5 mRNA. We found that 22Rv1
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Figure 1 Effects of androgen on reactive oxygen species (ROS)
production in 22Rv1 cells is abolished by inhibitors of NADPH
oxidase (NOX), diphenyleneiodonium (DPI) and apocynin, as well
as the general antioxidant N-acetylcysteine (NAC). (a) Nitroblue
tetrazolium (NBT) reduction assay. (b) Dihydroethidium (DHE)
staining top- fluorescent microscopy view ( 400) and bottom-
calculated relative fluorescent intensity. C¼ androgen-depleted
medium comprising phenol-free medium and 10% charcoal-
stripped fetal calf serum (CSFCS). R¼ same medium as Cþ10
nM R1881. RþB¼ same medium as Cþ10 nM R1881 and 10 mM
bicalutamide.
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(Figure 2). We then examined if the transcript levels
of these NOX is regulated by androgens. As shown in
Figure 2, androgens could significantly increase the
mRNA levels of NOX2 and NOX4 compared with
treatment with no androgens (P¼0.038 and 0.001 for
NOX2 and NOX4 respectively) or the combination of
R1881 and bicalutamide (P¼0.03 and 0.011 for NOX2
and NOX4 respectively) This was evident even at a very
low number of PCR cycles (Figure 2). In addition, we
verified the effect of androgens on the protein expression
of NOX2 using antibodies specific for NOX2 subunit
gp91
phox. Treatment with R1881 significantly increased
the expression of gp91
phox in 22Rv1 cells compared with
androgen deprivation (P¼0.0001) or the combination of
R1881 and bicalutamide (P¼0.002) (Figure 3a). The
androgen-regulated effect on the protein expression of
gp91
phox was also evident in-vivo in three different
xenograft models of human PC (CWR22, WISH-PC14
and WISH-PC23), in which the tumor bearing mice
were either castrated or implanted with slow release
testosterone pallets (Figure 3b).
Androgens increase the in-vitro and in-vivo protein
expression of p22
phox
The NOX complex consists of the membrane-associated
flavocytochrome b588 protein, which is composed of
gp91
phox and p22
phox and cytosolic components p47
phox,
p67
phox and p40
phox.
10 As we showed that androgens
induce the expression of NOX2 and NOX4, we wanted to
examine their effect on p22
phox, which is essential to all
the NOX family sub-members with the exception of
NOX5.
10 Treatment with androgens significantly in-
creased the expression of p22
phox compared with andro-
gen deprivation (P¼0.028) or the combination of R1881
and bicalutamide (P¼0.016) (Figure 4a). The androgen-
regulated effect on p22
phox expression was also evident
in-vivo, confirmed using three different xenograft models
of human PC (CWR22, WISH-PC14 and WISH-PC23),
in which the tumor-bearing mice were either castrated
or implanted with slow-release testosterone pallets
(Figure 4b). These results suggest that the p22
phox
catalytic subunit of NOX is a target for androgen
regulation.
The inhibition of NOX sensitizes 22rv1 cells to radiation
Finally, we examined in-vitro if abolishing the increased
NOX production of ROS (induced by androgens) by
means of short pretreatment with apocynin can eliminate
the relative radiation resistance of the cells conferred by
preconditioning with R1881. We found that incubation
with apocynin and R1881 fully restored the radio-
sensitivity compared with incubation with R1881 alone
(P¼0.0001). Treatment with apocynin induced even
better radiosensitization than bicalutamide, although
the latter was also very efficient (Figure 5). The radiation
sensitization effects of NOX inhibition is likely related to
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scavenging ROS using NAC, a non specific ROS
scavenger, achieved a similar effect (data not shown).
Collectively, these results indicate that reducing the basal
levels of ROS in PC cells in vitro, using specific NOX
inhibitors, can sensitize the cells to radiation across all
hormonal conditions and may thus, circumvent the need
for androgen deprivation as a means to enhance the
tumor response to radiation.
Discussion
The results presented here show that androgens can
stimulate NOX to produce ROS in prostate cancer cells.
In accordance with the model we previously proposed,
8
these elevated ROS levels induce adaptation to radiation.
Thus, by applying ADT or inhibition of NOX, the
sensitivity of androgen-stimulated PC cells to radiation
can be restored (Figure 6). As shown here, one of the
major sources of ROS generation in PC cells is the NOX
system. Accordingly, inhibition of NOX using apocynin
increases the response of PC cells to radiation (Figure 5).
Several studies have shown a variable profile of NOX
expression in PC. The expression of NOX2, NOX4 and
NOX5 by the 22Rv1 human PC cells used in our model is
in line with the findings of Kumar et al.,
9 who showed an
increased expression of NOX2, NOX4 and NOX5 mRNA
in PC3, LnCaP and DU145 human PC cells, and linked it
to their proliferative and survival capacity. Other studies
have also characterized the expression of NOX in-vitro in
PC and their functional significance. Thus, Brar et al.
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Figure 3 Androgens increase the protein expression of gp91
phox in human prostate cancer. (a) In-vitro (22Rv1 cells). C¼ androgen-depleted
medium comprising phenol-free medium and 10% charcoal-stripped fetal calf serum (CSFCS). R¼ same medium as Cþ10 nM R1881.
RþB¼ same medium as Cþ10 nM R1881 and 10 mM bicalutamide. (b) In-vivo. Aþ testosterone supplemented, A  castrated SCID mice.
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DU145 cells. NOX1 has been shown to be associated with
PC
19 and as a potent trigger of angiogenesis in DU145
xenograft model.
20 Tam et al.
21 showed hormonal
regulation of NOX in the normal ventral rat prostate.
In their model, castration up-regulated NOX1, NOX2
and NOX4. Nevertheless, to the best of our knowledge
the hormonal effects of androgens and androgen
deprivation on the expression of NOX and its ability to
generate ROS have not been tested in the human
prostate, in general and in PC, in particular. Using the
22Rv1 human androgen-responsive but not dependent
cell line, we could document that the mRNA expression
of NOX2 and NOX4, but not NOX5, was up-regulated by
androgens and downregulated by lack of androgens in
the culture media or with the concurrent use of
androgens and androgen-receptor blockers
(Figure 2). In addition, the protein expression of NOX2
(gp91
phox) was increased by androgens and decreased by
ADT, both in-vitro and in-vivo (Figure 3). In the absence
of available anti-NOX4 antibodies, we could not directly
test the effect of androgens and ADT on NOX4 protein
expression. Nevertheless, we could do so for gp22
phox—
an essential catalytic subunit of NOX2, and show that it
is regulated by androgens both in-vitro and in-vivo
(Figure 4).
There are several possibilities to explain how andro-
gens induce expression of NOX enzymes. The gene
expression of these enzymes may be directly regulated
by androgens, although in the rat NOX2 and NOX4
genes do not contain androgen-responsive elements.
21
Alternatively, androgens can induce the expression of
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Figure 4 Androgens increase the protein expression of p22
phox in human prostate cancer. (a) In-vitro (22Rv1 cells). C¼ androgen-depleted
medium comprising phenol-free medium and 10% charcoal-stripped fetal calf serum (CSFCS). R¼ same medium as Cþ10 nM R1881.
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be nuclear factor-kB, whose expression levels are
regulated by androgens.
22 Nuclear factor-kB have been
shown to increase NOX expression.
23 It is interesting to
note that, the positive effect of androgens on NOX
activity showed in this study may be unique to PC cells,
as Juliet et al.
24 showed that testosterone actually inhibit
superoxide production in macrophages, potentially
through an inhibitory effect on the expression of the
cytosolic subunits of NOX- p67
phox and p47
phox. In this
study we have shown that androgen can increase the
basal ROS levels through NOX2 and NOX4, an effect that
is blocked by apocynin or androgen receptor blockade.
Unlike severe or excessive accumulation of ROS that
triggers a pro-apoptotic toxic event in cancer cells,
25,26
reducing the basal ROS levels by means of apocynin or
ADT reset the adaptive molecular machinery of the cells
rendering it much more vulnerable to toxic oxidative
stress as induced by radiation therapy (8 and Figure 6)
The potential future clinical application of apocynin as
a radiation sensitizer is appealing. It is a natural organic
compound that acts as a NOX inhibitor by preventing
the assembly of its subunits.
27,28 Accordingly, it has
been shown to be effective in preventing the production
of the superoxide in human white blood cells.
29 It does
not, however, obstruct the phagocytic or other defense
roles of granulocytes including intracellular killing,
26
and so may be widely used as an inhibitor of
NOX.
30,31 Obviously, preclinical in-vivo studies are
needed before the use of apocynin as an alternative to
ADT for radiation sensitization in PC can be explored
in clinical trails, but our findings establish a proof-
of-principle for this concept.
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